Comparison of the treatment with paroxetine and reboxetine in panic disorder: A randomized, single-blind study

被引:32
作者
Bertani, A [1 ]
Perna, G [1 ]
Migliarese, G [1 ]
Di Pasquale, D [1 ]
Cucchi, M [1 ]
Caldirola, D [1 ]
Bellodi, L [1 ]
机构
[1] Vita Salute Univ, Hosp San Raffaele, Dept Neuropsychiat Sci, Ist Sci Osped San Raffaele,Anxiety Disorder Clin, I-20127 Milan, Italy
关键词
D O I
10.1055/s-2004-832593
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Serotonergic agents have greater effectiveness than nonadrenergic ones in the treatment of Panic Disorder (PD). However preliminary studies suggested that reboxetine might be effective in the treatment of PD. We compared the effectiveness and tolerability of reboxetine and paroxetine in the treatment of PD. Methods: Sixty-eight patients with PD were assigned to treatment groups in a single-blind, randomized design. Each patient was assessed at day 0 and 90 by the Panic Associated Symptoms Scale (PASS), the Sheehan Disability Scale (SDS) and the Fear Questionnaire (FQ). Side effects were also recorded. Results: Reduction of PASS scores was significantly greater in the paroxetine group than in the reboxetine one. Vice versa we did not find any significant differences for other outcome measures. Sexual dysfunction and weight gain were significantly less frequent in the reboxetine group. Conclusions: The results showed a greater effect of paroxetine on panic attacks than reboxetine, while no differences for anticipatory anxiety and avoidance were found, suggesting a different role of noradrenaline and serotonin in the treatment of PD.
引用
收藏
页码:206 / 210
页数:5
相关论文
共 30 条
[21]  
MODIGH K, 1992, J CLIN PSYCHOPHARM, V12, P251
[22]  
Montejo AL, 2001, J CLIN PSYCHIAT, V62, P10
[23]   A comparison of citalopram and paroxetine in the treatment of panic disorder: A randomized, single-blind study [J].
Perna, G ;
Bertani, A ;
Caldirola, D ;
Smeraldi, E ;
Bellodi, L .
PHARMACOPSYCHIATRY, 2001, 34 (03) :85-90
[24]   A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder [J].
Sasson, Y ;
Iancu, I ;
Fux, M ;
Taub, M ;
Dannon, PN ;
Zohar, J .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1999, 9 (03) :191-196
[25]   Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study [J].
Seedat, S ;
van Oudtshoorn, EV ;
Muller, JE ;
Mohr, N ;
Stein, DJ .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (05) :279-284
[26]  
Sheehan D.V., 1994, MINI INT NEUROPSYCHI
[27]  
Sheehan DV, 1996, J CLIN PSYCHIAT, V57, P51
[28]   The noradrenergic system in pathological anxiety: A focus on panic with relevance to generalized anxiety and phobias [J].
Sullivan, GM ;
Coplan, JD ;
Kent, JM ;
Gorman, JM .
BIOLOGICAL PSYCHIATRY, 1999, 46 (09) :1205-1218
[29]   Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder [J].
Versiani, M ;
Cassano, G ;
Perugi, G ;
Benedetti, A ;
Mastalli, L ;
Nardi, A ;
Savino, M .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (01) :31-37
[30]   Reboxetine: A pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor [J].
Wong, EHF ;
Sonders, MS ;
Amara, SG ;
Tinholt, PM ;
Piercey, MFP ;
Hoffmann, WP ;
Hyslop, DK ;
Franklin, S ;
Porsolt, RD ;
Bonsignori, A ;
Carfagna, N ;
McArthur, RA .
BIOLOGICAL PSYCHIATRY, 2000, 47 (09) :818-829